Schizophrenia – Unmet Need – Unmet Need – Treatment Resistant Schizophrenia (US/EU)
Most psychiatrists define TRS as a lack of response to at least two treatment changes. Currently, clozapine is the only approved drug for this condition, but its use is limited due to safety concerns associated with a black box warning, poor tolerability, and the need for regular blood monitoring. Additionally, a significant proportion of TRS patients fail to respond adequately to clozapine, leaving them with limited treatment options. The late-stage pipeline for TRS is sparse. Notably, Newron Pharmaceuticals is investigating evenamide as an add-on treatment to antipsychotics for TRS patients. The drug has shown positive efficacy and safety in Phase 2. With up to 30% of drug-treated schizophrenia patients being treatment-resistant, this patient segment represents a substantial commercial opportunity for safe and effective treatments.
Questions answered
- Which clinical/nonclinical attributes for a therapy will influence psychiatrists’ treatment decisions for TRS patients?
- How do psychiatrists rate the performance of key current therapies on treatment drivers and goals for TRS?
- What are the prevailing areas of unmet need in TRS?
- What are the key opportunities for drug development in TRS?
Product description
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Key feature
Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 32 European psychiatrists fielded in February 2025
Key companies: Otsuka Pharmaceutical, Lundbeck, Eli Lilly, Johnson & Johnson Innovative Medicine, AbbVie, Recordati
Key drugs: Clozapine, aripiprazole, risperidone, paliperidone palmitate, olanzapine, brexpiprazole, cariprazine
